Author

J. Marto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Kentsis· 1 shared A. Krivtsov· 1 shared B. Spitzer· 1 shared C. O'Donnell· 1 shared C. Reed· 1 shared C. Stutzke· 1 shared D. Peterle· 1 shared E. Still· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kentsis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Translocation of polyubiquitinated protein substrates by the hexameric Cdc48 ATPase

Z. Ji, H. Li, D. Peterle, J. A. Paulo, S. B. Ficarro, T. E. Wales, J. Marto, S. Gygi, J. R. Engen, T. A. Rapoport

This study elucidates how the Cdc48 ATPase complex unfolds and translocates polyubiquitinated protein substrates through cooperative binding with Ufd1/Npl4.

bioRxiv · Oct 21, 2021Biochemistry

LKB1 negatively regulates AKT1 signaling via DBC1 and TRB3

S. Andrabi, Z. Sarwar, S. A. Bhat, S. Q. Gillani, I. Reshi, M. Un Nisa, G. Adelmant, J. Marto

The paper identifies a signaling pathway where LKB1 inhibits AKT1 through DBC1 and TRB3, showing how PyST affects these interactions.

bioRxiv · Jul 3, 2019 · PreprintCell Biology

MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia

F. Brown, E. Still, P. Cifani, S. Takao, C. Reed, S. Ficarro, R. Koche, P. Romanienko, W. Mark, C. O'Donnell, B. Spitzer, C. Stutzke, A. Krivtsov, G. Pouliot, J. Marto, , A. Kentsis

This study identifies MEF2C phosphorylation as a marker of chemotherapy resistance in AML and shows that inhibiting this phosphorylation can overcome resistance in MEF2C-activated cells.

bioRxiv · Feb 9, 2017Cancer Biology